Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 446-560-3 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Remarks:
- expert statement
- Type of information:
- other: expert statement
- Adequacy of study:
- other information
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Objective of study:
- absorption
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Toxicokinetic statement for HEC 5725-DCF-Pyrimidine based on available toxicology data
- GLP compliance:
- no
- Details on absorption:
- Based on the provided data, the absorption of HEC 5725-DCF-Pyrimidine after oral administration is likely to be good after both oral and dermal administration. Dermal administration of 500 µL to the skin of three rabbits led to the death of two of the three animals within 24 hours, and in rats the dermal LD50 is approximately 300 mg/kg bw.
Repeated oral gavage administration led to decreased body weight at at 25 mg/kg bw/day in conjunction with local signs of irritation in the forestomach at 1, 5, and 25 mg/kg bw/day, although the majority of findings observed in the 28-day oral study may have been due simply to the local irritation observed in the stomach rather than to systemic toxicity of the test substance. - Conclusions:
- The substance is considered to be absorbed equally oral and dermal based on the available data.
Reference
Description of key information
toxicokinetic expert statement based on available toxicity data; the substance is equally absorbed via oral and dermal route
Key value for chemical safety assessment
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
